OakChart

Context Therapeutics Inc

CNTXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.2161+0.0291 (15.56%)
2026-11-12 02:24 CET
Market cap
19.86 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-43.89 USD m
Free cash flow, TTM
-34.03 USD m
EPS diluted, TTM
-0.47
P/E
-
Compare

Price

CNTX against its 20, 50 and 200-day averages
2050200beatmiss
1.002.003.0010.3M20.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CNTXclose 0.2220-day 0.2250-day 0.29200-day 1.390.22

94.0% under the 52-week high of 3.62 on 16 Mar 2026. 52-week low 0.18 on 6 Nov 2026. Last 15 sessions, 37.2% high to low

Volume 0.90× normal · the line is the 50-bar volume average

Profile

CNTX
52-week range, 1% of the way up
0.183.62

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

IndexRUT
Employees15
IPOOct 20, 2021
Beta1.80
ATR, 14d0.02
Rel volume0.90
Short float6.17%
Insider own17.17%
Inst own60.91%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap19.85M
Enterprise Value-14.35M
Income-43.89M
Sales0.00M
Book/sh0.34
Cash/sh0.37
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees15
IPOOct 20, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.64
P/C0.58
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio6.56
Current Ratio6.56
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.47
EPS next Y-0.41
EPS next Q-0.11
EPS this Y-17.30%
EPS next Y7.53%
EPS next 5Y-8.67%
EPS past 3/5Y25.81% -
Sales past 3/5Y- -
EPS Y/Y TTM-66.49%
Sales Y/Y TTM-
EPS Q/Q21.32%
Sales Q/Q-
EarningsNov 10 AMC
EPS/Sales Surpr.25.65% -

Ownership

Insider Own17.17%
Insider Trans0.00%
Inst Own60.91%
Inst Trans-8.89%
ROA-75.82%
ROE-84.26%
ROIC-141.41%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-0.28%
SMA50-25.86%
SMA200-84.50%
Trades-

Technical

Shs Outstand91.88M
Shs Float76.10M
Short Float6.17%
Short Ratio3.13
Short Interest4.70M
52W High3.62 -94.03%
52W Low0.18 20.06%
Volatility11.67% 11.29%
ATR (14)0.02
RSI (14)42.39
Beta1.80
Rel Volume0.90
Avg Volume1.50M
Volume1,352,891

Performance

Perf Week6.19%
Perf Month-21.42%
Perf Quarter-57.33%
Perf Half Y-90.84%
Perf YTD-85.30%
Perf Year-81.84%
Perf 3Y-79.67%
Perf 5Y-95.87%
Perf 10Y-
Recom1.20
Target Price4.12
Prev Close0.19
Price0.22
Change %15.56%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Sep 18, 2025InitiatedGGuggenheimBuy$5+2,213.7%
Apr 21, 2025InitiatedWWilliam BlairOutperform
Jan 08, 2025InitiatedJJMP SecuritiesMkt Outperform$4+1,751.0%
Nov 25, 2024InitiatedDD. Boral CapitalBuy$9+4,064.7%
May 16, 2024InitiatedPPiper SandlerOverweight$4.50+1,982.4%

Peers

Mkt cap
TickerCompanyMkt cap
JANXJanux Therapeutics Inc758.06M
CGEMCullinan Therapeutics Inc730.42M
INBXInhibrx Biosciences Inc1.33B
ATOSAtossa Therapeutics Inc20.26M
XNCRXencor Inc3.00B
MGNXMacrogenics Inc147.78M
OLMAOlema Pharmaceuticals Inc703.48M
CUECue Biopharma Inc135.55M
ALXOAlx Oncology Holdings Inc154.87M
GLSIGreenwich LifeSciences Inc236.17M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
RSSLGlobal X Russell 2000 ETFAUM: 1.43B
ITWOProShares Russell 2000 High Income ETFAUM: 178.20M
URTYProShares UltraPro Russell2000 3x SharesAUM: 277.82M

News

latest 14 of 200
  • Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress (GlobeNewswire) -6.64% +15.56%
  • Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202 (GlobeNewswire)
  • Context drops bispecific T-cell engager on cost-cutting initiative (Pharmaceutical Technology)
  • Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress (GlobeNewswire) +11.45% -27.27%
  • Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.82%
  • Context Therapeutics Added to Russell 2000 and Russell 3000 Indexes (GlobeNewswire) +9.79%
  • CNTX Hits Worst Day In History After Ovarian Cancer Trial Data But Analysts See Buying Opportunity In Dip (Stocktwits) -51.14%
  • Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 (GlobeNewswire)
  • Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.11%
  • Context Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +13.31%
  • Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 (GlobeNewswire)
  • Context Therapeutics Reports First Quarter 2026 Operating and Financial Results (GlobeNewswire)
  • Neogen Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary (Business Wire)
  • Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.080-0.108-0.0800.000.009
2026Q22026-08-05-0.150-0.092-0.1530.000.009
2026Q12026-05-06-0.090-0.111-0.0910.000.009
2025Q42026-03-23-0.140-0.105-0.1420.000.0010
2025Q32025-11-05-0.100-0.088-0.1020.000.008
2025Q22025-08-06-0.090-0.062-0.0930.000.004
2025Q12025-05-07-0.050-0.058-0.0480.000.005
2024Q42025-03-20-0.030-0.092-0.0370.000.005
2024Q32024-11-06-0.220-0.090-0.2170.000.003
2024Q22024-08-07-0.040-0.067-0.0410.000.003
2024Q12024-05-08-0.230-0.440-0.2300.000.001
2023Q42024-03-21-0.420-0.363-0.4240.000.003
2023Q32023-11-09-0.370-0.310-0.3680.000.003
2023Q22023-08-09-0.310-0.195-0.3140.000.002
2023Q12023-05-10-0.400-0.190-0.3950.000.002
2022Q42023-03-22-0.220-0.295-0.2230.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-3.690-3.380-0.6550.000.00
2022FY-0.930-1.047-0.9290.000.00
2023FY-1.500-1.443-1.5010.000.00
2024FY-0.460-0.580-0.4580.000.00
2025FY-0.380-0.350-0.3800.000.00
2026FY--0.446--0.00
2027FY--0.412--0.00
2028FY--0.488--2.45
2029FY--0.492--10.30
2030FY--0.456--24.58

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-117000.000.000.00
2026Q4S2026-11-107000.000.000.00
2026Q4S2026-08-067000.000.000.00
2026Q4S2026-05-077000.000.000.00
2026Q4S2026-03-296000.000.000.00
2026Q4S2026-03-247000.000.000.00
2026Q4S2025-12-197000.000.000.00
2026Q4S2025-11-116000.000.000.00
2026Q4S2025-11-106000.000.000.00
2026Q4R2026-11-11930-0.11-0.17-0.07
2026Q4R2026-11-10901-0.11-0.17-0.08
2026Q4R2026-11-04901-0.11-0.17-0.08
2026Q4R2026-11-02900-0.11-0.17-0.08
2026Q4R2026-10-20901-0.11-0.17-0.08

Estimate history

EPS, annual-0.5830.606-0.655-0.929-1.501-0.458-0.38-0.466
Period2019202020212022202320242025TTM
EPS, quarterly-0.217-0.037-0.048-0.093-0.102-0.142-0.091-0.153-0.08
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual10.9610.9615.96615.96615.96689.70491.87991.879
Period2019202020212022202320242025MRQ
Shares, quarterly74.99889.70489.70489.70491.87991.87991.87991.87991.879
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.160.120.050.010.010.000.000.00
Gross Profit-0.16-0.12-0.05-0.01-0.010.000.000.00
Selling, General and Administrative Excl. Other45.9239.5829.8725.0614.877.442.575.38
Research and Development37.1031.8622.7017.787.093.811.642.41
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-46.08-39.70-29.92-25.07-14.88-7.44-2.57-5.38
Interest Expense0.000.000.000.00-0.060.661.10
Unusual Expense0.000.000.000.000.502.95-9.88-0.09
Net Income Before Taxes-43.89-36.12-26.73-23.96-14.84-10.466.64-6.38
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-43.89-36.12-26.73-23.96-14.84-10.466.64-6.38
Net Income From Continuing Operations-43.89-36.12-26.73-23.96-14.84-10.466.64-6.38
Net Income-43.89-36.12-26.73-23.96-14.84-10.466.64-6.38
EPS (Recurring)-0.46-0.38-0.46-1.50-0.91-0.53-0.02-0.59
EPS (Basic, Before Extraordinaries)-0.47-0.38-0.46-1.50-0.93-0.650.61-0.58
EPS (Diluted)-0.47-0.38-0.46-1.50-0.93-0.650.61-0.58
EBITDA-45.92-39.58-29.87-25.06-14.87-7.44-2.57-5.38
Non-Operating Income (Expense)2.193.583.201.110.550.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.721.330.841.080.980.510.220.78
Shares Outstanding91.8891.8889.7015.9715.9715.9710.9610.96
Market Capitalization19.8619.8678.7518.0410.4142.4644.38-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.050.050.040.030.000.000.000.03
Gross Profit-0.05-0.05-0.04-0.03-0.00-0.00-0.00-0.03
Selling, General and Administrative Excl. Other7.9114.929.3113.7710.619.755.534.28
Research and Development5.7212.537.0211.848.727.833.462.52
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.96-14.97-9.34-13.80-10.61-9.76-5.53-4.31
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-7.62-14.56-8.68-13.03-9.69-8.83-4.58-3.34
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-7.62-14.56-8.68-13.03-9.69-8.83-4.58-3.34
Net Income From Continuing Operations-7.62-14.56-8.68-13.03-9.69-8.83-4.58-3.34
Net Income-7.62-14.56-8.68-13.03-9.69-8.83-4.58-3.34
EPS (Recurring)-0.08-0.15-0.09-0.14-0.10-0.09-0.05-0.04
EPS (Basic, Before Extraordinaries)-0.08-0.15-0.09-0.14-0.10-0.09-0.05-0.04
EPS (Diluted)-0.08-0.15-0.09-0.14-0.10-0.09-0.05-0.04
EBITDA-7.91-14.92-9.31-13.77-10.61-9.75-5.53-4.28
Non-Operating Income (Expense)0.340.410.660.780.920.930.950.97
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.460.530.410.330.320.390.290.23
Shares Outstanding91.8891.8891.8891.8891.8889.7089.7089.70
Market Capitalization19.8650.89240.72135.0686.9158.7754.9078.75

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments66.0094.4314.4535.5049.640.340.23
Short Term Receivables0.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets2.163.271.602.361.620.010.01
Total Current Assets68.1597.7016.0537.8551.260.350.24
Net Property, Plant & Equipment0.140.230.020.080.000.000.00
Total Investments and Advances0.000.000.000.000.050.000.00
Intangible Assets0.000.000.00-0.000.000.00
Other Assets0.200.200.000.030.000.120.03
Total Assets68.4998.1316.0637.9751.310.470.27
Short Term Debt Incl. Current Port. of LT Debt0.110.110.000.060.005.8821.84
Accounts Payable2.531.452.380.941.832.712.07
Other Current Liabilities5.381.191.812.221.210.960.20
Total Current Liabilities8.022.754.193.213.039.5524.11
Long Term Debt0.000.110.000.000.000.070.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.00
Total Liabilities8.022.864.193.213.039.6224.11
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.007.770.13
Common Equity60.4795.2711.8734.7648.27-16.92-23.96
Total Shareholders Equity60.4795.2711.8734.7648.27-9.15-23.83
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity60.4795.2711.8734.7648.27-9.15-23.83
Total Liabilities & Stockholders Equity68.4998.1316.0637.9751.310.470.27
Book Value Per Share0.661.060.742.183.02-1.54-2.19
Tangible Book Value Per Share0.661.060.742.183.02-1.54-2.19
Full-Time Employees15125972-
Price to Book Ratio0.640.940.980.270.88-1.31-
Return on Assets-43.36-46.81-88.71-33.24-40.401,793.65-
Return on Equity-46.39-49.89-102.79-35.74-53.46--
Return on Invested Capital-59.73-28.02-201.87-42.68-21.66--
Quick Ratio8.5035.553.8311.8016.900.040.01
Current Ratio8.5035.553.8311.8016.900.040.01

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-43.89-36.12-26.73-23.96-14.84-10.466.64-6.38
Depreciation0.240.120.050.010.01---
Other Funds (Non Cash)10.143.3315.591.131.553.88-9.002.99
Funds from Operations-33.51-32.67-11.08-22.82-13.27-6.57-2.35-3.40
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-0.466.28-3.481.78-0.28-2.221.320.56
Cash from Operating Activities-33.97-26.39-14.56-21.05-13.55-8.80-1.03-2.84
Capital Expenditures-8.56-2.03-14.760.00-0.540.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.00-0.250.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-8.56-2.03-14.760.00-0.54-0.250.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock0.00-0.02109.290.00-0.1058.391.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.00-0.02109.290.00-0.1058.391.000.00
Proceedsfrom Stock Options0.00-0.02109.290.00-0.1058.391.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.151.96
Change in Long Term Debt0.000.000.000.000.000.000.120.00
Issuance of Long Term Debt0.000.000.000.000.000.000.120.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities0.00-0.02109.290.00-0.1058.391.151.96
Net Change in Cash-42.53-28.4379.98-21.05-14.1949.340.11-0.88
Free Cash Flow-34.03-26.42-14.56-21.05-14.09-8.80-1.03-2.84
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments34.4142.9954.5366.0076.9483.52
Short Term Receivables0.000.000.900.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.662.632.892.161.923.23
Total Current Assets36.0745.6258.3268.1578.8686.75
Net Property, Plant & Equipment0.270.320.340.140.170.20
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.200.200.200.200.200.20
Total Assets36.5446.1358.8668.4979.2387.15
Short Term Debt Incl. Current Port. of LT Debt0.180.170.160.110.120.11
Accounts Payable1.603.292.472.532.722.40
Other Current Liabilities3.734.433.915.383.202.04
Total Current Liabilities5.507.886.538.026.044.56
Long Term Debt0.030.080.120.000.020.05
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities5.537.966.668.026.064.61
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity31.0138.1752.2060.4773.1782.54
Total Shareholders Equity31.0138.1752.2060.4773.1782.54
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity31.0138.1752.2060.4773.1782.54
Total Liabilities & Stockholders Equity36.5446.1358.8668.4979.2387.15
Book Value Per Share0.340.420.570.660.800.92
Tangible Book Value Per Share0.340.420.570.660.800.92
Full-Time Employees---15--
Price to Book Ratio0.640.973.981.851.050.65
Return on Assets-75.82-68.96-52.99-43.36-31.94-36.03
Return on Equity-84.26-76.14-56.19-46.39-33.68-37.25
Return on Invested Capital-24.56-38.06-16.59-21.54-13.24-10.69
Quick Ratio6.565.798.928.5013.0719.04
Current Ratio6.565.798.928.5013.0719.04

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-7.62-14.56-8.68-13.03-9.69-8.83
Depreciation0.050.050.040.110.000.00
Other Funds (Non Cash)0.467.030.412.240.350.42
Funds from Operations-7.12-7.48-8.24-10.67-9.34-8.41
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.540.47-3.191.732.762.57
Cash from Operating Activities-6.58-7.02-11.43-8.94-6.58-5.84
Capital Expenditures-2.00-4.52-0.04-2.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-2.00-4.52-0.04-2.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.000.000.000.000.00
Net Change in Cash-8.58-11.54-11.47-10.94-6.58-5.84
Free Cash Flow-6.58-7.04-11.47-8.94-6.58-5.84

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.17%4.7M76.1M1.52M
2026-10-155.61%4.3M76.1M1.55M
2026-09-306.19%4.7M76.1M2.00M
2026-09-159.09%6.9M76.0M2.63M
2026-08-318.51%6.5M76.0M2.82M
2026-08-148.26%6.3M76.0M2.54M
2026-07-317.05%5.8M82.8M2.30M
2026-07-158.01%6.6M82.8M2.27M
2026-06-303.88%3.2M82.8M1.77M
2026-06-151.03%0.9M82.8M1.09M
2026-05-291.08%0.9M82.8M864.06K
2026-05-151.42%0.9M64.7M846.42K
2026-04-301.38%0.9M65.0M1.04M
2026-04-151.33%0.9M65.0M1.32M
2026-03-311.70%1.1M65.0M1.61M
2026-03-131.98%1.3M65.0M1.60M
2026-02-271.77%1.2M65.0M1.49M
2026-02-131.78%1.2M65.0M1.45M
2026-01-301.17%0.7M61.0M1.21M
2026-01-150.85%0.5M61.0M818.82K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-10SEC
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-058-KCurrent report2026-08-05SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-318-KCurrent report2026-07-29SEC
2026-07-31SCHEDULE 13G/ASEC
2026-07-27SCHEDULE 13GSEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-268-KCurrent report2026-06-24SEC
2026-06-158-KCurrent report2026-06-15SEC
2026-05-188-KCurrent report2026-05-14SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-14SCHEDULE 13GSEC
2026-05-14SCHEDULE 13G/ASEC
2026-05-12SCHEDULE 13G/ASEC
2026-05-08SCHEDULE 13G/ASEC
2026-05-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-018-KCurrent report2026-04-30SEC
2026-04-28ARSAnnual report to security holders. 2025-12-31SEC
2026-04-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-28SEC
2026-04-17PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-24SEC
2026-04-028-KCurrent report2026-04-02SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Nextech Invest Ltd.8.08%
Deep Track Capital, LP8.08%
Soleus Capital Management, L.P.7.69%
BlackRock, Inc.6.71%
Avidity Partners Management LP5.44%
FRANKLIN RESOURCES INC4.14%
VANGUARD CAPITAL MANAGEMENT LLC3.74%
Octagon Capital Advisors LP3.32%
Blue Owl Capital Holdings LP3.19%
TCG Crossover Management, LLC2.92%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.06%
iShares Russell 2000 ETF2.54%
Franklin Biotechnology Discovery Fund1.52%
Fidelity Small Cap Index Fund1.10%
iShares Russell 2000 Growth ETF0.95%
VANGUARD RUSSELL 2000 INDEX FUND0.59%
VANGUARD EXTENDED MARKET INDEX FUND0.57%
iShares Micro-Cap ETF0.34%
Fidelity Extended Market Index Fund0.30%
Schwab Small-Cap Index Fund0.25%

OakChart. CNTX. Cached 15 minutes.

Some panels did not load: insider.